Basket Trials (as of June 2022)

ENGOT-GYN4/NOGGO/EXPRESSION IX

Leading group: NOGGO

Clinical Trial Study: Expression IX-Longterm survival with gynecological cancer

Planned number of patients: 1000 (100-200 per country)

Participating groups: BGOG, A-AGO, MITO, TRSGO, NSGO, SwissGO, CEEGOG, ANZGOG

 

ENGOT-GYN3/AGO/LIO

Leading group: AGO

Clinical Trial Study: LIO-1: A phase 1b/2, open-label study to evaluate the safety and efficacy of lucitanib in combination with nivolumab in patients with an advanced, metastatic solid tumor

Planned number of patients: 161

Participating groups: BGOG, GEICO, MITO, NOGGO

 

ENGOT-GYN2/GINECO/BOUQUET

Leading group: GINECO

Clinical Trial Study: A multicenter, multi-arm, open-label, genomics-driven phase II study evaluating the clinical benefit of molecularly targeted therapies alone or in combination in patients with progressive locally-advanced or metastatic rare gynecologic tumors after one line of systemic therapy

Planned number of patients: 20 patients per cohort

Participating groups: AGO, BGOG, CEEGOG, GEICO, MITO, MaNGO, Swiss GO, TRSGO, NCRI 

 

ENGOT-GYN1/NCRI/ATARI

Leading group: NCRI

Clinical Trial Study: ATARI Trial: ATr inhibitor in combination with olaparib in gynaecological cancers with ARId1A loss or no loss  

Planned number of patients: 116

Participating groups: GINECO, Princes Margaret Consortium Canada